Genitope: Safety board recommends MyVax trial for lymphoma continue

By E. Janene Geiss

Philadelphia, July 28 - Genitope Corp. announced late Thursday that its independent Data Safety Monitoring Board reviewed the second planned interim analysis of data for efficacy in its pivotal phase 3 clinical trial for treatment of follicular non-Hodgkin's lymphoma and recommended that the trial continue as planned.

The clinical trial will be completed by December 2007, according to a company news release.

The trial evaluates the safety and efficacy of the company's lead product candidate, MyVax personalized immunotherapy, in patients with previously untreated follicular non-Hodgkin's lymphoma.

The trial compares patients treated with MyVax personalized immunotherapy to patients treated with a nonspecific immunotherapy control, officials said.

Genitope is a Redwood City, Calif., biotechnology company focused on treating cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.